Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 8:23 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 313–336 of 584 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: OCT Clear all
Completed Phase 4 Interventional Results available

The IAI-OCTA Study; a Study of OCT-Angiography Analysis Efficacy

NCT03022292
View directory record Official record
Conditions
Wet Macular Degeneration
Interventions
Aflibercept Ophthalmic, optovue angiovue
Drug · Device
Lead sponsor
University of California, Los Angeles
Other
Eligibility
50 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 6, 2022 · Synced Oct 19, 2026, 8:23 PM EDT
Completed No phase listed Observational

Blood Storage Related Mortality and Adverse Effects in Trauma Patients

NCT07341139
View directory record Official record
Conditions
Transfusion Adverse Reaction, Major Trauma, Blood Product Transfusion for All Conditions
Interventions
Not listed
Lead sponsor
Kocaeli City Hospital
Government
Eligibility
18 Years to 75 Years
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Aug 7, 2026 · Synced Oct 19, 2026, 8:23 PM EDT
Completed No phase listed Observational Results available

Evaluation of Vitrectomy for Diabetic Macular Edema

NCT00709319
View directory record Official record
Conditions
Diabetic Retinopathy, Diabetic Macular Edema
Interventions
Not listed
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
18 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
48
States / cities
Irvine, California • Loma Linda, California • Palm Springs, California + 39 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2019 · Synced Oct 19, 2026, 8:23 PM EDT
Completed Phase 4 Interventional Results available

Effect of Nepafenac on Post-operative Macular Swelling Following Uncomplicated Cataract Surgery

NCT00494494
View directory record Official record
Conditions
Cystoid Macular Edema
Interventions
Standard Care, nepafenac
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
50 Years and older
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 12, 2011 · Synced Oct 19, 2026, 8:23 PM EDT
Not listed No phase listed Observational

OCT and Scaffold Embedding After NC Balloon

NCT03106961
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Bioresorbable vascular scaffolds, OCT, non-compliant ballooning
Device
Lead sponsor
St. Francis Hospital, New York
Other
Eligibility
Not listed
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Roslyn, New York
Source: ClinicalTrials.gov public record
Updated Apr 11, 2017 · Synced Oct 19, 2026, 8:23 PM EDT
Completed No phase listed Observational

NOTAL-OCT V.2.5 vs Commercial OCT in AMD Patients

NCT03969303
View directory record Official record
Conditions
AMD - Age-Related Macular Degeneration, Diabetic Macular Edema
Interventions
Notal Vision Optical Coherence Tomography Device Version 2.5 (NOTAL-OCT V2.5)
Device
Lead sponsor
Notal Vision Ltd.
Industry
Eligibility
18 Years and older
Enrollment
287 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 12, 2020 · Synced Oct 19, 2026, 8:23 PM EDT
Terminated Phase 3 Interventional Results available

Suprachoroidal Injection of Triamcinolone Acetonide With IVT Aflibercept in Subjects With Macular Edema Following RVO

NCT02980874
View directory record Official record
Conditions
Macular Edema, Retinal Vein Occlusion
Interventions
suprachoroidal CLS-TA, suprachoroidal sham, IVT aflibercept
Drug
Lead sponsor
Clearside Biomedical, Inc.
Industry
Eligibility
18 Years and older
Enrollment
460 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
58
States / cities
Peoria, Arizona • Phoenix, Arizona • Tucson, Arizona + 51 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2021 · Synced Oct 19, 2026, 8:23 PM EDT
Completed Not applicable Interventional Results available

Optical Coherence Tomography (OCT) Based Screening of Esophagus and Gastroesophageal Junction

NCT01401699
View directory record Official record
Conditions
Barrett's Esophagus
Interventions
Optical Frequency Domain Imaging (OFDI)
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
Not listed
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 18, 2023 · Synced Oct 19, 2026, 8:23 PM EDT
Terminated Phase 2 Interventional Results available

A Phase II Study Comparing The Efficacy Of Venetoclax + Fulvestrant Vs. Fulvestrant In Women With Estrogen Receptor-Positive, Her2-Negative Locally Advanced Or Metastatic Breast Cancer Who Experienced Disease Recurrence Or Progression During Or After CDK4/6 Inhibitor Therapy

NCT03584009
View directory record Official record
Conditions
Estrogen Receptor-positive (ER+)/Human Epidermal Growth Factor Receptor (HER2)-Negative Locally Advanced or Metastatic Breast Cancer
Interventions
Venetoclax, Fulvestrant
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older · Female only
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
21
States / cities
Phoenix, Arizona • Springdale, Arkansas • La Jolla, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2022 · Synced Oct 19, 2026, 8:23 PM EDT
Recruiting Not applicable Interventional

Collagen Cross-linking in Keratoconus

NCT03760432
View directory record Official record
Conditions
Keratoconus
Interventions
Laser Custom Corneal Collagen Cross-Linking
Procedure
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 9, 2025 · Synced Oct 19, 2026, 8:23 PM EDT
Terminated Phase 2 Interventional Results available

Atacicept in Subjects With Optic Neuritis

NCT00624468
View directory record Official record
Conditions
Optic Neuritis
Interventions
Atacicept, Placebo matched to atacicept
Drug
Lead sponsor
EMD Serono
Industry
Eligibility
18 Years to 60 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
8
States / cities
Birmingham, Alabama • Aurora, Colorado • Fairfield, Connecticut + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2016 · Synced Oct 19, 2026, 8:23 PM EDT
Active, not recruiting Phase 3 Interventional

An Open-label Study to Investigate ECUR-506 in Male Babies Less Than 9 Months of Age With Neonatal Onset OTC Deficiency

NCT06255782
View directory record Official record
Conditions
Ornithine Transcarbamylase Deficiency, Ornithine Transcarbamylase Deficiency Disease, Ornithine Carbamoyltransferase Deficiency (Disorder), Urea Cycle Disorders, Inborn
Interventions
ECUR-506
Genetic
Lead sponsor
iECURE, Inc.
Industry
Eligibility
24 Hours to 7 Months · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
6
States / cities
Los Angeles, California • Aurora, Colorado • Atlanta, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 19, 2026, 8:23 PM EDT
Terminated Phase 1 Interventional

Hepatocyte Transplantation for Liver Based Metabolic Disorders

NCT01345578
View directory record Official record
Conditions
Metabolic Diseases
Interventions
human hepatocyte transplantation, Preparative Radiation Therapy
Drug · Radiation
Lead sponsor
Ira Fox
Other
Eligibility
Up to 21 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2022
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 7, 2022 · Synced Oct 19, 2026, 8:23 PM EDT
Completed No phase listed Observational

Swept Source OCT Imaging With the DREAM VG-OCT

NCT05876689
View directory record Official record
Conditions
Eye Diseases, Myopia, Glaucoma
Interventions
DREAM OCT
Device
Lead sponsor
Robert T. Chang, MD
Other
Eligibility
18 Years and older
Enrollment
154 participants
Timeline
2023 – 2024
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Nov 25, 2024 · Synced Oct 19, 2026, 8:23 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Retinal and Retinal Pigment Epithelium (RPE) Autoimmunity in Age-related Macular Degeneration (AMD)

NCT00931489
View directory record Official record
Conditions
Age Related Macular Degeneration
Interventions
ranibizumab (Lucentis(R))
Drug
Lead sponsor
Lawrence S. Morse, MD
Other
Eligibility
50 Years and older
Enrollment
131 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2014
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 19, 2026, 8:23 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Imaging of Retinochoroidal Vasculature in Patients Being Assessed for Cardiovascular Disease

NCT05082402
View directory record Official record
Conditions
Cardiovascular Diseases, Retina; Change
Interventions
Swept Source Optical Coherence Tomography Angiography
Diagnostic Test
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 95 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 19, 2026, 8:23 PM EDT
Completed Not applicable Interventional Results available

OCT Pilot in Esophagus

NCT03434834
View directory record Official record
Conditions
Barrett Esophagus
Interventions
optical coherence tomography
Device
Lead sponsor
Duke University
Other
Eligibility
18 Years to 80 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 6, 2021 · Synced Oct 19, 2026, 8:23 PM EDT
Terminated No phase listed Observational

Natural History of Optic Neuritis

NCT01851434
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Not listed
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
18 Years to 50 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
2
States / cities
Bethesda, Maryland • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Sep 29, 2022 · Synced Oct 19, 2026, 8:23 PM EDT
Enrolling by invitation No phase listed Observational

Posterior Cervical Fixation Study

NCT04770571
View directory record Official record
Conditions
Degenerative Disc Disease, Craniocervical Injuries, Cervical Radiculopathy, Cervical Disc Disease, Cervical Fusion, Cervical Spine Disease, Cervical Myelopathy, Cervical Instabilities Spine, Thoracic Injury
Interventions
observational study
Device
Lead sponsor
NuVasive
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
7
States / cities
Orange, California • Hartford, Connecticut • Hyattsville, Maryland + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2025 · Synced Oct 19, 2026, 8:23 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Treating Cancer-Related Fatigue Through Systematic Light Exposure (Light for Fatigue Study)

NCT03119363
View directory record Official record
Conditions
Multiple Myeloma, Fatigue
Interventions
AYO light glasses (Experimental), AYO light glasses (Comparator)
Device
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
194 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2022
U.S. locations
3
States / cities
Hackensack, New Jersey • New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 16, 2022 · Synced Oct 19, 2026, 8:23 PM EDT
Completed Not applicable Interventional

Drug Eluting Stent for the Management of PERipheral Arterial Disease Of the SFA (DESPERADO-SFA Study)

NCT02734836
View directory record Official record
Conditions
Peripheral Arterial Disease
Interventions
Balloon Angioplasty, Optical Coherence Tomography
Device · Other
Lead sponsor
Arkansas Heart Hospital
Other
Eligibility
18 Years to 99 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Jun 26, 2019 · Synced Oct 19, 2026, 8:23 PM EDT
Recruiting Phase 2 Interventional

Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients

NCT03587844
View directory record Official record
Conditions
Mycosis Fungoides, Lymphomatoid Papulosis, Sezary Syndrome
Interventions
brentuximab vedotin
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
8
States / cities
Stanford, California • Basking Ridge, New Jersey • Middletown, New Jersey + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2026 · Synced Oct 19, 2026, 8:23 PM EDT
Completed Not applicable Interventional

Multi-modality Imaging in Acute Myocardial Infarction

NCT02926755
View directory record Official record
Conditions
Acute Myocardial Infarction, STEMI, Coronary Artery Disease, Atherosclerotic Plaque Disruption With Thrombosis of Artery
Interventions
Coronary Angiography
Procedure
Lead sponsor
Corewell Health East
Other
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Royal Oak, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 10, 2019 · Synced Oct 19, 2026, 8:23 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Comparative Study of the Tomey OA-2000, Tomey CASIA2, and the LenStar LS900

NCT06065072
View directory record Official record
Conditions
Cataract, Aphakic Eye, Pseudophakia
Interventions
Optical measurement
Device
Lead sponsor
Tomey Corporation
Industry
Eligibility
22 Years and older
Enrollment
167 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Woburn, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 3, 2023 · Synced Oct 19, 2026, 8:23 PM EDT